1437TiP Phase Ib/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in Progress)
Conference Paper
Full Text
Duke Authors
Cited Authors
- Park, H; Bekaii-Saab, T; Kim, S; Kamath, S; Pishvaian, M; Ford, J; Zhen, D; Mayor, J; Lux, C; Tan, Q; Strickler, J
Published Date
- September 2021
Published In
Volume / Issue
- 32 /
Start / End Page
- S1073 - S1074
Published By
International Standard Serial Number (ISSN)
- 0923-7534
Digital Object Identifier (DOI)
- 10.1016/j.annonc.2021.08.1546